David Wang
Direktor/Vorstandsmitglied bei BIOVAXYS TECHNOLOGY CORP.
Vermögen: 92 540 $ am 30.04.2024
Profil
David Wang is currently the Chief Executive Officer at Encounter Technology Ltd., Director at BioVaxys Technology Corp., and Director at BioVaxys LLC.
Previously, he worked as the Chief Executive Officer at Beijing Century Medical.
Mr. Wang holds an MBA from the University of International Business.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
BIOVAXYS TECHNOLOGY CORP
1,03% | 08.02.2023 | 1 492 575 ( 1,03% ) | 92 540 $ | 30.04.2024 |
Aktive Positionen von David Wang
| Unternehmen | Position | Beginn |
|---|---|---|
| BIOVAXYS TECHNOLOGY CORP. | Direktor/Vorstandsmitglied | - |
BioVaxys LLC
 BioVaxys LLC BiotechnologyHealth Technology BioVaxys LLC is a clinical stage biotechnology company, which engages in the development of immunotherapeutic vaccines for antiviral and individualized cancer therapy. It focuses on multihaptenized autologous vaccine that will initially be developed and marketed for melanoma and ovarian cancer. The company was founded by James Passin, Kenneth Kovan and David Berd and is headquartered in New York, NY. | Direktor/Vorstandsmitglied | - |
| Encounter Technology Ltd. | Vorstandsvorsitzender | - |
Ehemalige bekannte Positionen von David Wang
| Unternehmen | Position | Ende |
|---|---|---|
| Beijing Century Medical | Vorstandsvorsitzender | - |
Ausbildung von David Wang
| University of International Business | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| BIOVAXYS TECHNOLOGY CORP. | Non-Energy Minerals |
| Private Unternehmen | 3 |
|---|---|
| Beijing Century Medical | |
BioVaxys LLC
BioVaxys LLC BiotechnologyHealth Technology BioVaxys LLC is a clinical stage biotechnology company, which engages in the development of immunotherapeutic vaccines for antiviral and individualized cancer therapy. It focuses on multihaptenized autologous vaccine that will initially be developed and marketed for melanoma and ovarian cancer. The company was founded by James Passin, Kenneth Kovan and David Berd and is headquartered in New York, NY. | Health Technology |
| Encounter Technology Ltd. |
